Stryker (NYSE:SYK) Now Covered by Analysts at KeyCorp

Equities research analysts at KeyCorp started coverage on shares of Stryker (NYSE:SYKGet Rating) in a report released on Wednesday, The Fly reports. The brokerage set a “sector weight” rating on the medical technology company’s stock.

Several other equities analysts also recently weighed in on the company. BTIG Research raised their target price on Stryker from $232.00 to $268.00 in a research report on Wednesday, December 21st. Canaccord Genuity Group downgraded Stryker from a “buy” rating to a “hold” rating and decreased their target price for the company from $225.00 to $220.00 in a research report on Tuesday, November 1st. Cowen raised their target price on Stryker from $233.00 to $283.00 in a research report on Wednesday, December 14th. TheStreet upgraded Stryker from a “c+” rating to a “b” rating in a research report on Tuesday, November 22nd. Finally, Wells Fargo & Company raised their target price on Stryker from $248.00 to $281.00 and gave the company an “overweight” rating in a research report on Monday, December 12th. Seven equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $260.68.

Stryker Stock Down 0.7 %

Shares of SYK stock opened at $255.75 on Wednesday. The stock’s 50-day simple moving average is $243.85 and its 200-day simple moving average is $223.70. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.19 and a current ratio of 2.04. The firm has a market capitalization of $96.78 billion, a PE ratio of 39.77, a P/E/G ratio of 2.87 and a beta of 0.94. Stryker has a fifty-two week low of $188.84 and a fifty-two week high of $279.28.

Stryker (NYSE:SYKGet Rating) last issued its earnings results on Monday, October 31st. The medical technology company reported $2.12 EPS for the quarter, missing analysts’ consensus estimates of $2.24 by ($0.12). Stryker had a return on equity of 22.27% and a net margin of 13.69%. The company had revenue of $4.48 billion during the quarter, compared to analysts’ expectations of $4.46 billion. During the same quarter in the previous year, the company earned $2.20 EPS. The firm’s quarterly revenue was up 7.7% compared to the same quarter last year. Equities analysts expect that Stryker will post 9.17 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Srikant M. Datar sold 600 shares of Stryker stock in a transaction that occurred on Wednesday, November 2nd. The shares were sold at an average price of $216.71, for a total value of $130,026.00. Following the completion of the transaction, the director now owns 5,161 shares in the company, valued at $1,118,440.31. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Srikant M. Datar sold 600 shares of Stryker stock in a transaction that occurred on Wednesday, November 2nd. The shares were sold at an average price of $216.71, for a total value of $130,026.00. Following the completion of the transaction, the director now owns 5,161 shares in the company, valued at $1,118,440.31. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP M Kathryn Fink sold 6,571 shares of the business’s stock in a transaction that occurred on Wednesday, January 11th. The stock was sold at an average price of $257.69, for a total transaction of $1,693,280.99. Following the sale, the vice president now owns 9,264 shares of the company’s stock, valued at approximately $2,387,240.16. The disclosure for this sale can be found here. Insiders sold 80,079 shares of company stock worth $19,354,832 over the last 90 days. 6.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Stryker

A number of institutional investors have recently modified their holdings of the business. AMG National Trust Bank grew its stake in shares of Stryker by 18.0% during the 3rd quarter. AMG National Trust Bank now owns 18,650 shares of the medical technology company’s stock worth $3,778,000 after purchasing an additional 2,851 shares during the period. J.W. Cole Advisors Inc. lifted its holdings in Stryker by 5.0% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 2,757 shares of the medical technology company’s stock valued at $558,000 after purchasing an additional 132 shares in the last quarter. Lincoln National Corp lifted its holdings in Stryker by 8.0% in the 2nd quarter. Lincoln National Corp now owns 5,668 shares of the medical technology company’s stock valued at $1,128,000 after purchasing an additional 421 shares in the last quarter. Asset Dedication LLC purchased a new position in Stryker in the 3rd quarter valued at about $184,000. Finally, SG Americas Securities LLC lifted its holdings in Stryker by 117.7% in the 2nd quarter. SG Americas Securities LLC now owns 18,095 shares of the medical technology company’s stock valued at $3,600,000 after purchasing an additional 9,782 shares in the last quarter. 77.10% of the stock is owned by institutional investors and hedge funds.

About Stryker

(Get Rating)

Stryker Corp. operates as a medical technology company. It operates through the following segments: Orthopaedics & Spine and MedSurg & Neurotechnology. The Orthopaedics & Spine segment provides implants for use in total joint replacements, such as hip, knee, and shoulder, and trauma and extremities surgeries.

Read More

The Fly logo

Analyst Recommendations for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.